Methoxyflurane

src: www.sentinellemedical.com

Methoxyflurane, marketed as Penthrane, is a halogenated ether that was in clinical use as a volatile inhalational anesthetic from its introduction in 1960 until the late 1970s. It was first synthesized in the late 1940s by William T. Miller and his team of chemists following their involvement in the Manhattan Project.

Methoxyflurane is an extremely potent and highly lipid-soluble anesthetic agent, characterized by very slow induction (onset of action) and emergence (offset or dissipation) times. It is non-flammable, has relatively mild hemodynamic effects, and it does not predispose the heart to rhythm disturbances. It is, however, a significant respiratory depressant. Methoxyflurane has powerful analgesic (pain-relieving) properties at well below full anesthetic doses. It was utilized in self-administration devices for obstetric analgesia, in a manner that foreshadowed the patient-controlled analgesia infusion pumps of today.

The biodegradation of methoxyflurane produces inorganic fluoride and dichloroacetic acid (DCAA). The combined effects of these two compounds may be responsible for the toxicity of methoxyflurane to some of the major organs of the human body. Methoxyflurane was determined to be damaging to the kidneys in a dose-dependent response and damaging to the liver at anesthetic doses in 1973, and the drug was abandoned as a general anesthetic in the late 1970s. In 1999, the manufacturer discontinued distribution of methoxyflurane in the United States and Canada, and on September 6, 2005, the Food and Drug Administration determined that it should be withdrawn from the market for safety concerns. It is however still used in Australia and Ireland as an emergency analgesic for the initial management of pain due to acute trauma, as well as for brief painful procedures such as changing of wound dressings or for transport of injured people.

Video Methoxyflurane

Medical use

Methoxyflurane has been extensively used since the 1970s in Australia as an emergency analgesic for short-term use, mostly by the Australian and New Zealand Defence Forces, and the Australian ambulance services. The drug is currently only available from one manufacturer (Medical Developments International, Melbourne, Victoria, Australia). It is self-administered to children and adults using the Penthrox inhaler, a hand-held inhaler device, known as "the green whistle". A non-opioid alternative to morphine, it is also easier to use than nitrous oxide. As of 2010, methoxyflurane was listed under the Pharmaceutical Benefits Scheme for the initial management of pain due to acute trauma, as well as for brief painful procedures such as changing of wound dressings or for patient transport. A portable, disposable, single-use inhaler device (the Penthrox inhaler), along with a single 3 milliliter brown glass vial of methoxyflurane is provided in doctor's kits that allows conscious hemodynamically stable patients (including children over the age of 5 years) to self-administer the drug, under supervision.

Each 3 milliliter dose lasts approximately 30 minutes. Pain relief begins after 6-8 breaths and continues for several minutes after stopping inhalation. The maximum recommended dose is 6 milliliters per day or 15 milliliters per week because of the risk of cumulative dose-related nephrotoxicity, and it should not be used on consecutive days. Despite the potential for renal impairment when used at anesthetic doses, no significant adverse effects have been reported in the literature when it is used at the lower doses (up to 6 milliliters) used for producing analgesia and sedation. Due to the risk of organ (especially renal) toxicity, methoxyflurane is contraindicated in patients with pre-existing kidney disease or diabetes mellitus, and is not recommended to be administered in conjunction with tetracyclines or other potentially nephrotoxic or enzyme-inducing drugs.

Maps Methoxyflurane

Chemical and physical properties

With a molecular formula of C₃H₄Cl₂F₂O and a condensed structural formula of CHCl₂CF₂OCH₃, the International Union of Pure and Applied Chemistry (IUPAC) name for methoxyflurane is 2,2-dichloro-1,1-difluoro-1-methoxyethane. It is a halogenated ether in form of a clear, colorless liquid, and its vapor has a strong fruity aroma. It is miscible with ethanol, acetone, chloroform, diethyl ether, and fixed oils. It is soluble in rubber.

With a minimum alveolar concentration (MAC) of 0.16%, methoxyflurane is an extremely potent anesthetic agent. It is a powerful analgesic agent at well below full anesthetic concentrations. Because of its low volatility and very high boiling point (104.8 °C at 1 atmosphere), methoxyflurane has a low vapor pressure at ambient temperature and atmospheric pressure. It is therefore quite difficult to vaporize methoxyflurane using conventional anesthetic vaporizers.

The carbon-fluorine bond, a component of all organofluorine compounds, is the strongest chemical bond in organic chemistry. Furthermore, this bond becomes shorter and stronger as more fluorine atoms are added to the same carbon on a given molecule. Because of this, fluoroalkanes are some of the most chemically stable organic compounds.

src: www.dovepress.com

Pharmacokinetics

Methoxyflurane has a very high lipid solubility (oil:gas partition coefficient of around 950), which gives it very slow pharmacokinetics (induction and emergence characteristics); this being undesirable for routine application in the clinical setting. Initial studies performed in 1961 revealed that in unpremedicated healthy individuals, induction of general anesthesia with methoxyflurane-oxygen alone or with nitrous oxide was difficult or even impossible using the vaporizers available at that time. It was found to be necessary to administer an intravenous anesthetic agent such as sodium thiopental to ensure a smooth and rapid induction. It was further found that after thiopental induction, it was necessary to administer nitrous oxide for at least ten minutes before a sufficient amount of methoxyflurane could accumulate in the bloodstream to ensure an adequate level of anesthesia. This was despite using high flow (liters/minute) of nitrous oxide and oxygen, and with the vaporizers delivering the maximum possible concentration of methoxyflurane.

Similar to its induction pharmacokinetics, methoxyflurane has very slow and somewhat unpredictable emergence characteristics. During initial clinical studies in 1961, the average time to emergence after discontinuation of methoxyflurane was 59 minutes after administration of methoxyflurane for an average duration of 87 minutes. The longest time to emergence was 285 minutes, after 165 minutes of methoxyflurane administration.

src: spcare.bmj.com

Pharmacodynamics

Cardiovascular effects

The effects of methoxyflurane on the circulatory system resemble those of diethyl ether. In dogs, methoxyflurane anesthesia causes a moderate decrease in blood pressure with minimal changes in heart rate, and no significant effect on blood sugar, epinephrine, or norepinephrine. Bleeding and increased arterial partial pressure of carbon dioxide (PaCO₂) both induce further decreases in blood pressure, as well as increases in blood glucose, epinephrine and norepinephrine. In humans, methoxyflurane produces some decrease in blood pressure, but cardiac output, stroke volume, and total peripheral resistance are only minimally depressed. Its effect on the pulmonary circulation is negligible, and it does not predispose the heart to cardiac dysrhythmias.

Respiratory effects

Unlike diethyl ether, methoxyflurane is a significant respiratory depressant. In dogs, methoxyflurane causes a dose-dependent decrease in respiratory rate and a marked decrease in respiratory minute volume, with a relatively mild decrease in tidal volume. In humans, methoxyflurane causes a dose-dependent decrease in tidal volume and minute volume, with respiratory rate relatively constant. The net effect of these changes is profound respiratory depression, as evidenced by CO₂ retention with a concomitant decrease in arterial pH (this is referred to as a respiratory acidosis) when anesthetized subjects are allowed to breathe spontaneously for any length of time.

Gastrointestinal effects

In a series of 500 consecutive obstetric patients, Boisvert and Hudon observed vomiting in 12 (4.8%) patients during or after administration of methoxyflurane anesthesia. These findings compared favorably with those reported for cyclopropane (42%), trichloroethylene (28%) and halothane (4.6%). In another study of 645 obstetric patients, Romagnoli and Korman observed 8 cases (1.2%) of postoperative vomiting, one of whom was retching before the administration of the anesthetic.

Analgesic effects

Although the high blood solubility of methoxyflurane is often undesirable, this property makes it useful in certain situations--it persists in the lipid compartment of the body for a long time, providing sedation and analgesia well into the postoperative period. There is substantial data to indicate that methoxyflurane is an effective analgesic and sedative agent at subanesthetic doses. Supervised self-administration of methoxyflurane in children and adults can briefly lead to deep sedation, and it has been used as a patient controlled analgesic for painful procedures in children in hospital emergency departments. During childbirth, administration of methoxyflurane produces significantly better analgesia, less psychomotor agitation, and only slightly more somnolence than trichloroethylene.

In 1968, Robert Wexler of Abbott Laboratories developed the Analgizer, a disposable inhaler that allowed the self-administration of methoxyflurane vapor in air for analgesia. The Analgizer consisted of a polyethylene cylinder 5 inches long and 1 inch in diameter with a 1 inch long mouthpiece. The device contained a rolled wick of polypropylene felt which held 15 milliliters of methoxyflurane. Because of the simplicity of the Analgizer and the pharmacological characteristics of methoxyflurane, it was easy for patients to self-administer the drug and rapidly achieve a level of conscious analgesia which could be maintained and adjusted as necessary over a period of time lasting from a few minutes to several hours. The 15 milliliter supply of methoxyflurane would typically last for two to three hours, during which time the user would often be partly amnesic to the sense of pain; the device could be refilled if necessary. The Analgizer was found to be safe, effective, and simple to administer in obstetric patients during childbirth, as well as for patients with bone fractures and joint dislocations, and for dressing changes on burn patients. When used for labor analgesia, the Analgizer allows labor to progress normally and with no apparent adverse effect on Apgar scores. All vital signs remain normal in obstetric patients, newborns, and injured patients. The Analgizer was widely utilized for analgesia and sedation until the early 1970s, in a manner that foreshadowed the patient-controlled analgesia infusion pumps of today. The Analgizer inhaler was withdrawn in 1974, but use of methoxyflurane as a sedative and analgesic continues in Australia and New Zealand in the form of the Penthrox inhaler. Trials of methoxyflurane as an analgesic in emergency medicine are going on in the UK.

Central nervous system effects

Similar to other inhalational anesthetics, the exact mechanism of action is not clearly defined and likely involves multiple molecular targets in the brain and spinal cord. Methoxyflurane is a positive allosteric modulator of GABA_A and glycine receptors as demonstrated in electrophysiology studies. This mechanism is shared with alcohols that produce general anesthesia.

src: www.penthrox.co.uk

Biodegradation and toxicity

The first report of nephrotoxicity appeared in 1964, when Paddock and colleagues reported three cases of acute renal insufficiency, two of whom were found to have calcium oxalate crystals in the renal tubules at autopsy. In 1966, Crandell and colleagues reported a series in which 17/95 (18%) of patients developed an unusual type of nephropathy after operations in which methoxyflurane was used as a general anesthetic. This particular type of renal insufficiency was characterized by vasopressin-resistant high-output renal failure (production of large volumes of poorly concentrated urine) with a negative fluid balance, pronounced weight loss, elevation of serum sodium, chloride, osmolality and blood urea nitrogen. The urine of these patients was of a relatively fixed specific gravity and an osmolality very similar to that of the serum. Furthermore, the high urine output persisted a challenge test of fluid deprivation. Most cases resolved within 2-3 weeks, but evidence of renal dysfunction persisted for more than one year in 3 of these 17 cases (18%), and more than two years in one case (6%).

Reports of severe and even fatal hepatotoxicity related to the use of methoxyflurane began to appear in 1966. These reports prompted anesthesiologists to subject this agent to intense and systematic scrutiny. A study published in 1973 by Cousins and Mazze demonstrated that compared with halothane, methoxyflurane produces dose-dependent and deleterious abnormalities in renal function. The authors showed that subclinical nephrotoxicity occurred following methoxyflurane at minimum alveolar concentration (MAC) for 2.5 to 3 hours (2.5 to 3 MAC hours), while overt toxicity was present in all patients at dosages greater than five MAC hours. This landmark study provided a model that would be used for the assessment of the nephrotoxicity of volatile anesthetics for the next two decades.

The biodegradation of methoxyflurane begins immediately after the onset of exposure. The kidney and liver toxicity observed after anesthetic doses is attributable to one or more metabolites produced by O-demethylation of methoxyflurane. Significant products of this catabolic process include methoxyfluoroacetic acid (MFAA), dichloroacetic acid (DCAA), and inorganic fluoride. Methoxyflurane nephrotoxicity is dose dependent and irreversible, resulting from O-demethylation of methoxyflurane to fluoride and DCAA. This effect is so predictable and reproducible that methoxyflurane now serves as a pharmacologic model of fluoride-related nephrotoxicity, one with which newer drugs are compared. It is not entirely clear whether the fluoride itself is toxic--it may simply be a surrogate measure for some other toxic metabolite. The concurrent formation of inorganic fluoride and DCAA is unique to methoxyflurane biotransformation compared with other volatile anesthetics, and this combination is more toxic than fluoride alone. This may explain why fluoride formation from methoxyflurane is associated with nephrotoxicity, while fluoride formation from other volatile anesthetics (such as enflurane and sevoflurane) is not. Furthermore, the concurrent use of tetracyclines and methoxyflurane has been reported to result in fatal renal toxicity.

Based on the findings of these and other studies in the early 1970s, the current consensus is that the use of methoxyflurane should be restricted only to healthy individuals, in situations where it offers specific advantages and even then, only at dosages less than 2.5 MAC hours. Partly because of these warnings, but also because of the development of newer volatile anesthetics such as enflurane, isoflurane, desflurane and sevoflurane, the clinical use of methoxyflurane as a general anesthetic in humans was largely abandoned in the mid-1970s.

The National Institute for Occupational Safety and Health maintains a recommended exposure limit for methoxyflurane as waste anesthetic gas of 2 ppm (13.5 mg/m³) over 60 minutes.

src: slideplayer.com

History

All of the currently used volatile anesthetic agents are organofluorine compounds. Aside from the synthesis of Freon (Thomas Midgley, Jr. and Charles F. Kettering, 1928) and the discovery of Teflon (Roy J. Plunkett, 1938), the field of organofluorine chemistry had not attracted a great deal of attention up to 1940 because of the extreme reactivity of elemental fluorine, which had to be produced in situ for use in chemical reactions. The development of organofluorine chemistry was a spin-off from the Manhattan Project, during which elemental fluorine was produced on an industrial scale for the first time.

The need for fluorine arose from the need to separate the isotope²³⁵U from ²³⁸U because the former, present in natural uranium at a concentration of less than 1% is fissile (capable of sustaining a nuclear chain reaction of nuclear fission with thermal neutrons), whereas the latter is not. Members of the MAUD Committee (especially Francis Simon and Nicholas Kurti) proposed the use of gaseous diffusion for isotope separation, since, according to Graham's law the rate of diffusion is inversely proportional to molecular mass. After an extensive search, uranium hexafluoride, UF₆, was determined to be the most suitable compound of uranium to be used for the gaseous diffusion process. Elemental fluorine is needed in the production of UF₆.

Significant obstacles had to be overcome in the handling of both fluorine and UF₆. Before the K-25 gaseous diffusion plant could be built, it was first necessary to develop non-reactive chemical compounds that could be used as coatings, lubricants and gaskets for the surfaces which would come into contact with the UF₆ gas (a highly reactive and corrosive substance). William T. Miller, professor of organic chemistry at Cornell University, was co-opted to develop such materials, because of his expertise in organofluorine chemistry. Miller and his team developed several novel non-reactive chlorofluorocarbon polymers that were used in this application.

Charles Suckling synthesized halothane in 1951. Halothane was the first organofluorine anesthetic agent to be introduced into clinical practice in 1956. Miller and his team continued to develop organofluorine chemistry after the end of World War II and methoxyflurane was synthesized in 1948.

src: i.ytimg.com

Notes

src: www.penthrox.co.uk

References

src: spcare.bmj.com

Further reading

• Brennan, R.; Pearlstein, A.; Miller, S. (1988). "Computed tomography of the kidneys in a patient with methoxyflurane abuse". Journal of computer assisted tomography. 12 (1): 155-156. doi:10.1097/00004728-198801000-00033. PMID 3335658. 
• Clark, R.; Beard, A.; Thompson, D. (1979). "Renal function in newborns and mothers exposed to methoxyflurane analgesia for labor and delivery". Anesthesiology. 51 (5): 464-466. doi:10.1097/00000542-197911000-00020. PMID 496064. 
• Corbett, T.; Ball, G. (1971). "Chronic exposure to methoxyflurane: A possible occupational hazard to anesthesiologists". Anesthesiology. 34 (6): 532-537. doi:10.1097/00000542-197106000-00012. PMID 5556243. 
• Crankshaw DP, Eagle A, Komesaroff D (2004). "Methoxyflurane dosage with the Penthrox inhaler for analgesia during short painful procedures (abstract)". Anaesth. Intensive Care. 32 (3): 428. 
• Dahlgren, B. (1979). "Fluoride concentrations in urine of delivery ward personnel following exposure to low concentrations of methoxyflurane". Journal of Occupational Medicine. 21 (9): 624-626. PMID 490224. 
• Dahlgren, B. (1980). "Hepatic and renal effects of low concentrations of methoxyflurane in exposed delivery ward personnel". Journal of Occupational Medicine. 22 (12): 817-819. doi:10.1097/00043764-198012000-00017. PMID 7218059. 
• Dahlgren, B.; Olander, L.; Ovrum, P. (1979). "Pollution of delivery ward air by nitrous oxide--methoxyflurane". American Industrial Hygiene Association journal. 40 (8): 666-672. doi:10.1080/15298667991430136. PMID 495468. 
• De Francisco, C. (1971). "Pentrane dependence: A case report". The British Journal of Psychiatry. 119 (553): 609-610. doi:10.1192/bjp.119.553.609. PMID 5143658. 
• Edmunds, D.; Rosen, M. (1975). "Inhalation sedation for conservative dentistry. A comparison between nitrous oxide and methoxyflurane". British dental journal. 139 (10): 398-402. doi:10.1038/sj.bdj.4803643. PMID 1059442. 
• Elder, B.; Beal, H.; Dewald, W.; Cobb, S. (1971). "Exacerbation of subclinical myasthenia by occupational exposure to an anesthetic". Anesthesia and Analgesia. 50 (3): 383-387. doi:10.1213/00000539-197105000-00023. PMID 5103772. 
• Kharasch, E.; Hankins, D.; Thummel, K. (1995). "Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity". Anesthesiology. 82 (3): 689-699. doi:10.1097/00000542-199503000-00011. PMID 7879937. 
• Klemmer, P.; Hadler, N. (1978). "Subacute fluorosis: A consequence of abuse of an organofluoride anesthetic". Annals of Internal Medicine. 89 (5 Pt 1): 607-611. doi:10.7326/0003-4819-89-5-607. PMID 717928. 
• Komesaroff D; Crankshaw DP (2004). Methoxyflurane analgesia with the Penthrox Inhaler: Emergency Department and Hospital Ward Applications. Teaching and Research Conference. Victoria University of Technology, Melbourne, Australia. 
• Laird SM, Gray BM. Intermittent inhalation of methoxyflurane and trichloroethylene as an analgesic in burns dressings procedures. Br. J. Anaesth. 1971; 43: 149-59.
• Lindblad P, Zack M, Adami HO, Ericson A (1992). "Maternal and perinatal risk factors for Wilms' tumor: a nationwide nested case control study in Sweden". International Journal of Cancer. 51 (1): 38-41. doi:10.1002/ijc.2910510108. PMID 1314230. 
• Major, V.; Rosen, M.; Mushin, W. (1967). "Concentration of methoxyflurane for obstetric analgesia by self-administered intermittent inhalation". British Medical Journal. 4 (5582): 767-770. doi:10.1136/bmj.4.5582.767. PMC 1749043 . PMID 6081001. 
• Metropolitan Ambulance Service/Rural Ambulance Service. Clinical practice guideline D020. Version 4, 2005. Methoxyflurane (Penthrane).
• Miller WT (1981). "My early days in fluorine chemistry" (PDF). Journal of Fluorine Chemistry. 18 (4): 305-21. doi:10.1016/S0022-1139(00)82652-4. 
• Novak, M.; Roth, A.; Levine, M. (1988). "Calcium oxalate retinopathy associated with methoxyflurane abuse". Retina (Philadelphia, Pa.). 8 (4): 230-236. doi:10.1097/00006982-198808040-00002. PMID 3231916. 
• National Institute for Occupational Safety and Health. Pocket guide to chemical hazards, methoxyflurane. Publication number 2005-149.
• Rosen, M.; Latto, P.; Asscher, A. (1972). "Kidney function after methoxyflurane analgesia during labour". British Medical Journal. 1 (5792): 81-83. doi:10.1136/bmj.1.5792.81. PMC 1789263 . PMID 5007074. 
• Rosen, M.; Mushin, W.; Jones, P.; Jones, E. (1969). "Field trial of methoxyflurane, nitrous oxide, and trichloroethylene as obstetric analgesics". British Medical Journal. 3 (5665): 263-267. doi:10.1136/bmj.3.5665.263. PMC 1984095 . PMID 4895340. 
• Toomath, R.; Morrison, R. (1987). "Renal failure following methoxyflurane analgesia". The New Zealand medical journal. 100 (836): 707-708. PMID 3452163. 

src: pbs.twimg.com

External links

• Sheffield Museum of Anaesthesia: the Analgizer
• Medical Developments International Limited: Penthrox (methoxyflurane)
• Centers for Disease Control and Prevention: NIOSH Pocket Guide to Chemical Hazards

Source of article : Wikipedia